The roleof Neprilysin inhibitor in the treatment of heart failure

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorEsmaeili, Mehrdad
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház, Aneszteziológiai és Intenziv Therápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2022-01-19T11:23:56Z
dc.date.available2022-01-19T11:23:56Z
dc.date.created2021-05-26
dc.description.abstractHeart failure is characterized by the presence of signs and symptoms due to congestion or inadequate cardiac output all leading to activation of various neurohormonal system such as RAAS and SNS. The treatment of HF solely depends on underlying cause. Drugs such as ACEi , ARB, beta blockers are all been used for many years. Natriuretic peptides activation and release during HF are proved to be beneficial due to the fact that these are diuretics, vasodialators, supress the RAAS and SNS and etc. Certainly prolonging the NPs half life would alleviate much of the symptoms and decrease the morbidity as well as mortality of HF hence inhibiting the neprilysin as enzyme degrading the NPs is a big step in cardiology pharmacotherapy.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent36hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/328029
dc.language.isoenhu_HU
dc.subjectNeprilysin inhibitorshu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleThe roleof Neprilysin inhibitor in the treatment of heart failurehu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)